Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab - Suffredini, Dante A.; Lee, Jung-Min; Peer, Cody J.; Pratt, Drew; Kleiner, David E.; Elinoff, Jason M.; Solomon, Michael A. (BMC pulmonary medicine, 2018)
Keywords: Analysis; Angiogenesis; Antibodies, Monoclonal - therapeutic use; Autopsy; Cancer therapies; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - pathology; Case Report; Cediranib; Cervical cancer; Cervix; Clinical trials; Critical Care Medicine; Diagnosis; Dosage and administration; Drug therapy; Durvalumab; Dyspnea; Fatal Outcome; Female; Heart failure; Heart rate; Humans; Immunotherapy; Intensive; Internal Medicine; Ligands; Lung - blood supply; Lung - pathology; Lung - physiopathology; Lung cancer; Lung diseases; Lung Neoplasms - complications; Lung Neoplasms - secondary; Medicine; Medicine & Public Health; Metastasis; Middle Aged; Monoclonal antibodies; Neoplastic Cells, Circulating - pathology; PD-1 protein; PD-L1 protein; Pneumology/Respiratory System; Pulmonary arteries; Pulmonary hypertension; Pulmonary tumor thrombotic microangiopathy; Pulmonary Veno-Occlusive Disease - etiology; Pulmonary Veno-Occlusive Disease - pathology; Pulmonology; Quinazolines - therapeutic use; Respiratory critical care; Risk factors; Targeted cancer therapy; Thrombosis; Thrombotic Microangiopathies - etiology; Thrombotic Microangiopathies - pathology; Thrombotic microangiopathy; Tumors; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - pathology; Vascular endothelial growth factor; Veno-occlusive disease; Women's health; Pulmonary tumor thrombotic microangiopathy; Durvalumab; Pulmonary hypertension; Cediranib; Cervical cancer